Mechanism of Action:
LEQVIO® is the first and only siRNA (small interfering RNA)
therapy for LDL-C reduction that selectively targets the liver1
-
Works differently than other LDL-C–lowering treatments as a complement to statins1
-
Prevents the formation of the PCSK9 protein that promotes the degradation of LDL receptors1
-
Allows for greater uptake of LDL-C into hepatocytes1
-
Reaches undetectable levels in circulation within 48 hours of administration1

Explore the unique mechanism
of action of LEQVIO
THERE'S MORE TO KNOW ABOUT LEQVIO
Gain insights into
LEQVIO safety

LDL-C, low-density lipoprotein
cholesterol; RNA, ribonucleic acid.